Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_04568 |
| Species: | Homo sapiens |
| Position : | chr8:128910869-128911521 |
| Year: | 2025 |
| Title: | Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| PMID: | 38760567 |
| Tissue: | blood |
| Tissue Ontology ID: | UBERON:0000178 |
| Cell Source: | K-562 |
| CVCL ID: | CVCL_0004 |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| High Throughput Method: | RNA-seq; pooled CRISPRi screen; CRISPR genetic screen |
| Low Throughput Method: | CRISPRi, Flow Cytometry, qRT-PCR; CRISPRi |
| Target gene : | MYC |
| TF name : | NA |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_02292 | chr8:128750000-129000000 | breast | malignant cell | prostate cancer |